Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EW9Y | ISIN: US74006W2070 | Ticker-Symbol:
NASDAQ
23.04.25
21:59 Uhr
36,590 US-Dollar
0,000
0,00 %
1-Jahres-Chart
PRAXIS PRECISION MEDICINES INC Chart 1 Jahr
5-Tage-Chart
PRAXIS PRECISION MEDICINES INC 5-Tage-Chart

Aktuelle News zur PRAXIS PRECISION MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.04.Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)1
08.04.Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies1
03.04.Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)123BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln
24.03.Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting1
04.03.Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)186BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
03.03.Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate1
03.03.Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts2
28.02.Praxis Precision Medicines Plunges 39% After Study Termination Recommendation4
28.02.Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Update on Essential3 and Corporate Update211BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
28.02.Praxis Precision Medicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
28.02.Praxis Precision Medicines, Inc. - 10-K, Annual Report-
28.02.Praxis Precision Medicines, Inc. - 8-K, Current Report-
11.02.The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts3
11.02.Deutsche Bank sets $111 target for Praxis Precision shares10
04.02.Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)127BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
29.01.Praxis Precision Medicines, Inc. - 8-K, Current Report1
21.01.Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts1
13.01.Praxis Precision Medicines, Inc.: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities978Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide...
► Artikel lesen
23.12.24Praxis Precision Medicines files for automatic mixed securities shelf3
18.12.24Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome216Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1